ABT
US EQUITY
Health Care
Health Care Equipment
CIK: 1800
Abbott Laboratories (ABT) Quant Factor Diagnostic & Fair Value Model
Abbott Laboratories (Ticker: ABT) is listed in the Health Care sector (Health Care Equipment). Below is its point-in-time financial profile, valuation multiples, and cross-sectional factor diagnostics.
$103.70
+1.16%
Latest Close (2026-10-23)
Market Cap: $3.79M
P/E Ratio: 42.5
Momentum Strength
3M / 12M
-0.76%
1M: +2.60%
12M: -18.95%
Quality (ROE)
Point-in-Time
+4.68%
Trailing Return on Equity
Technical Trend
RSI 14
60.8
SMA50: $105.17
SMA200: $102.22
Valuation Multiplier
Trailing
42.5
Premium Multiple (> 30x P/E)
📊
Valuation & Multi-Factor Diagnostic
Premium Multiple (> 30x P/E)
ABT trades at 42.5x P/E, reflecting market-implied growth expectations for forward revenue and cash flow.
⚡
Benchmark Factor Strategy
S&P 500 Momentum Alpha Strategy
This strategy applies cross-sectional momentum and quality factor filters across large-cap US equities.
📈 Daily Candlestick & Volume Quant Chart
Interactive lightweight price action & volume breakdown over recent 90 trading days.
均线多头 (MA20/50)
Piotroski F-Score: 6/9 (Moderate Financial Health)
Official Point-in-Time Financial Filing History
Zero Lookahead Bias: Every financial metric is timestamped at the exact moment officially published to the market.
备案 CIK: 1800 · 10-K 年报 / 10-Q 季报
| Form | Period End | Filing Timestamp (Point-in-Time) | Revenue | Net Income | Operating CF | EPS (Diluted) |
|---|---|---|---|---|---|---|
| 10-Q | 2026-03-31 | 2026-04-29 | $11.16B | $1.08B | $1.31B | $0.61 |
| 10-Q | 2025-12-31 | 2026-04-29 | - | - | - | - |
| 10-Q | 2025-03-31 | 2026-04-29 | $10.36B | $1.32B | $1.42B | $0.76 |
| 10-K | 2025-12-31 | 2026-02-20 | $44.33B | $6.52B | $9.57B | $3.72 |
| 10-K | 2024-12-31 | 2026-02-20 | $41.95B | $13.40B | $8.56B | $7.64 |
| 10-K | 2023-12-31 | 2026-02-20 | $40.11B | $5.72B | $7.26B | $3.26 |
| 10-Q | 2025-09-30 | 2025-10-29 | $11.37B | $1.64B | $6.25B | $0.94 |
| 10-Q | 2024-12-31 | 2025-10-29 | - | - | - | - |
💡 Methodology & Frequently Asked Questions
Key reference details regarding Abbott Laboratories (ABT) valuation multiples, momentum factors, and point-in-time filing conventions.
How should ABT's current valuation multiple be interpreted? ↓
ABT trades at a trailing P/E of 42.5x within the Health Care sector (premium multiple (> 30x p/e)). Valuation multiples are computed using trailing-twelve-month GAAP earnings against the latest close price.
What are ABT's key momentum and technical factor indicators? ↓
As of the latest close, ABT shows a 1-month return of +2.60%, 3-month return of -0.76%, and 12-month return of -18.95%, with a 14-day RSI of 60.8. Momentum factors reflect short- and intermediate-term price velocity across the equity cross-section.
What is Point-in-Time (PIT) financial data and why does it matter for ABT? ↓
Point-in-Time indexing aligns corporate fundamentals with their official public filing timestamps (Form 10-Q/10-K) rather than accounting period-end dates. This methodology eliminates lookahead bias in historical equity backtests.
How can ABT be incorporated into systematic factor models? ↓
ABT can be evaluated within customized multi-factor models or screened against cross-sectional filters (such as momentum quintiles and return on equity) to analyze historical turnover and risk-adjusted return.